Literature DB >> 18173977

Cardiovascular risk, hypertension, and NSAIDs.

William B White1.   

Abstract

During the past 2 years, a great deal of evaluation has been conducted on the cardiovascular (CV) effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase (COX)-2 inhibitors. This review focuses on the effects of the NSAIDs and COX-2 inhibitors on blood pressure and CV events. Clinical trial databases for NSAIDs and COX-2 inhibitors have shown varying levels of destabilization of blood pressure control in treated hypertensive patients as well as variable incident rates of the development of arrhythmias, congestive heart failure, myocardial infarction, and stroke. Nonselective and COX-2 selective NSAIDs can be used carefully in arthritis patients with hypertension and stable CV disorders (excluding congestive heart failure and moderate to severe kidney dysfunction) when the individual clinical benefit of anti-inflammatory therapy outweighs the CV and gastrointestinal risk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18173977     DOI: 10.1007/s11916-007-0229-x

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  69 in total

1.  Effects of celecoxib and naproxen on renal function in the elderly.

Authors:  A Whelton; G Schulman; C Wallemark; E J Drower; P C Isakson; K M Verburg; G S Geis
Journal:  Arch Intern Med       Date:  2000-05-22

2.  Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation.

Authors:  Jan Steffel; Matthias Hermann; Helen Greutert; Steffen Gay; Thomas F Lüscher; Frank Ruschitzka; Felix C Tanner
Journal:  Circulation       Date:  2005-03-28       Impact factor: 29.690

3.  COX-2-derived prostacyclin modulates vascular remodeling.

Authors:  R Daniel Rudic; Derek Brinster; Yan Cheng; Susanne Fries; Wen-Liang Song; Sandra Austin; Thomas M Coffman; Garret A FitzGerald
Journal:  Circ Res       Date:  2005-05-19       Impact factor: 17.367

Review 4.  Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia.

Authors:  E Fosslien
Journal:  Crit Rev Clin Lab Sci       Date:  2000-10       Impact factor: 6.250

5.  Nonsteroidal anti-inflammatory drug use and acute myocardial infarction.

Authors:  Daniel H Solomon; Robert J Glynn; Raisa Levin; Jerry Avorn
Journal:  Arch Intern Med       Date:  2002-05-27

6.  Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis.

Authors:  Douglas J Watson; Thomas Rhodes; Bing Cai; Harry A Guess
Journal:  Arch Intern Med       Date:  2002-05-27

Review 7.  Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning.

Authors:  Roberto Bolli; Ken Shinmura; Xian-Liang Tang; Eitaro Kodani; Yu-Ting Xuan; Yiru Guo; Buddhadeb Dawn
Journal:  Cardiovasc Res       Date:  2002-08-15       Impact factor: 10.787

8.  The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin.

Authors:  Stephen E Kimmel; Jesse A Berlin; Muredach Reilly; Jane Jaskowiak; Lori Kishel; Jesse Chittams; Brian L Strom
Journal:  J Am Coll Cardiol       Date:  2004-03-17       Impact factor: 24.094

9.  Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.

Authors:  J I Schwartz; K Vandormael; M P Malice; R N Kalyani; K C Lasseter; G B Holmes; B J Gertz; K M Gottesdiener; M Laurenzi; K-J Redfern; K Brune
Journal:  Clin Pharmacol Ther       Date:  2002-07       Impact factor: 6.875

10.  Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?

Authors:  Steven A Grover; Louis Coupal; Hanna Zowall
Journal:  Hypertension       Date:  2004-11-15       Impact factor: 10.190

View more
  4 in total

1.  Inhibition of nuclear factor kappaB activation and cyclooxygenase-2 expression by aqueous extracts of Hispanic medicinal herbs.

Authors:  Robert A Orlando; Amanda M Gonzales; Lucy A Hunsaker; Carolina R Franco; Robert E Royer; David L Vander Jagt; Dorothy J Vander Jagt
Journal:  J Med Food       Date:  2010-08       Impact factor: 2.786

2.  The relation between total joint arthroplasty and risk for serious cardiovascular events in patients with moderate-severe osteoarthritis: propensity score matched landmark analysis.

Authors:  Bheeshma Ravi; Ruth Croxford; Peter C Austin; Lorraine Lipscombe; Arlene S Bierman; Paula J Harvey; Gillian A Hawker
Journal:  BMJ       Date:  2013-10-30

3.  Hypouricemic and arthritis relapse-reducing effects of compound tufuling oral-liquid in intercritical and chronic gout: A double-blind, placebo-controlled, multicenter randomized trial.

Authors:  Zhijun Xie; Huaxiang Wu; Xiaoqing Jing; Xiuyang Li; Yasong Li; Yongmei Han; Xiangfu Gao; Xiaopo Tang; Jing Sun; Yongshen Fan; Chengping Wen
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

4.  Evaluation of Bloodletting Cupping Therapy in the Management of Hypertension.

Authors:  Moawia M Al-Tabakha; Farah Tariq Sameer; Mai Hafiz Saeed; Rahaf Montaser Batran; Nada Tarek Abouhegazy; Alaa A Farajallah
Journal:  J Pharm Bioallied Sci       Date:  2018 Jan-Mar
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.